Stem Cell Therapeutics Announces Share Consolidation Proposal

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), announces today that consistent
with the Company's corporate objective of the acquisition and development of
additional stem cell-based therapies, and in order to attract the capital
required to support this objective, management and the board of directors
recommend the consolidation of the outstanding shares.


Consolidation will permit the issuance of additional securities not currently
permitted under $0.10 per share that has limited the Company's options. The
consolidation is generally expected to be advantageous to the Company's
corporate objectives and in attracting investors to the opportunities that may
emerge from the Company's rebuilding. A meeting of shareholders will be held on
December 20th, 2012 to vote on the recommendation of the board to consolidate
the outstanding common shares on the basis of a ratio to be proposed by the
board of directors in the range of one post-consolidation common share for each
10 to 30 outstanding pre-consolidation common shares. 


The meeting will be held at the Offices of McCarthy Tetrault LLP, Toronto
Dominion Bank Tower, 53rd Floor, J.J. Robinette Boardroom, TD Centre, 66
Wellington Street West, Toronto, ON M5K 1E6, on December 20, 2012, at 10:00 am
(Toronto time). Shareholders will receive the Information Circular and proxy
form shortly. Shareholders may vote by phoning in their election, or by internet
or mail, and are also invited to attend the meeting should they wish. Questions
related to this proposal may be emailed to David Allan, Executive Chairman.


The board of directors recommends the consolidation as being in the Company's
interest and an important step in meeting the objectives for the repositioning
of the Company.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) is a Canadian commercialization
receptor company in the business of developing stem cell-based therapeutics
through partnerships with research institutions or technology transfer
organizations. The Company's corporate objectives include the analysis and
acquisition of additional stem cell-related development opportunities and
securing capital for the advancement of the licensed or acquired products. In
October 2012 SCT became a member of the 20-member Centre for Commercialization
of Regenerative Medicine ("CCRM") consortium. SCT has extensive expertise and
experience in the stem cell biotechnology sector based on the intellectual
property of Dr. Samuel Weiss in stem cell research. SCT proposes to build upon
the foundational technologies by acquiring additional early-stage clinical or
late-stage preclinical candidates. SCT's Traumatic Brain Injury product,
NTx(R)-428, is currently in a Phase II clinical trial. For more information,
visit: www.stemcellthera.com


Caution Regarding Forward-Looking Information: 

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, the "forward-looking statements"). These
forward-looking statements relate to, among other things, SCT's objectives,
goals, targets, strategies, intentions, plans, beliefs, estimates and outlook,
and can, in some cases, be identified by the use of words such as "believe,"
"anticipate," "expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations, projections
or other characterizations of future events or circumstances are forward-looking
statements. These statements reflect management's current beliefs and are based
on information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: uncertainties and risks related
to, the availability of capital, changes in capital markets, uncertainties
related to clinical trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product liability,
unproven markets for technologies in development, the cost and supply of raw
materials, management of growth, effects of payers'' willingness to pay for
products, risks related to regulatory matters and risks related to intellectual
property matters. Additional information about these factors and about the
material factors or assumptions underlying such forward-looking statements may
be found in the body of this news release, as well as under the heading "Risk
Factors" contained in SCT's 2010 annual information form. SCT cautions that the
foregoing list of important factors that may affect future results is not
exhaustive. 


When relying on SCT's forward-looking statements to make decisions with respect
to SCT, investors and others should carefully consider the foregoing factors and
other uncertainties and potential events. Such forward-looking statements are
based on a number of estimates and assumptions which may prove to be incorrect,
including, but not limited to, assumptions regarding the availability of
financing for research and development companies in addition to general business
and economic conditions. These risks and uncertainties should be considered
carefully and investors and others should not place undue reliance on the
forward-looking statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be reasonable
assumptions, SCT cannot provide assurance that actual results will be consistent
with these forward-looking statements. SCT undertakes no obligation to update or
revise any forward-looking statement. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
[e-mail]
www.stemcellthera.com